We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“What both of these studies provide is an extension of what we saw from the pivotal trials. We continue to see safety, [and] we continue to see efficacy in the real world as well as with continued access in a much larger cohort of patients. I think this provides very reassuring data that the way it's being rolled out seems to be along the lines that one would've envisioned.”
“It's also important to point out that the criteria for bleeding through the registry was much more stringent than the MVARC criteria. So, in addition to these being numerically lower than what we saw in TRISCEND II, this is a more inclusive definition. I think those results are even better than what the numbers suggest.”
“This is the largest analysis of early T-TEER experience to date. TriClip is very safe and effective with a significant improvement in quality of life at 30 days with very low rates of mortality, heart failure hospitalization, bleeding, conduction disturbances, or device thrombosis.”
No takes yet. Share an insight, caveat, or question.
Manesh R. Patel (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: